Compugen (NASDAQ:CGEN) Issues Quarterly Earnings Results

Compugen (NASDAQ:CGEN) announced its earnings results on Tuesday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.20), Zacks reports. Compugen had a return on equity of 2.62% and a net margin of 2.67%. The company had revenue of $17.13 million for the quarter, compared to analyst estimates of $17.67 million. During the same period last year, the firm earned ($0.11) earnings per share.

Compugen Price Performance

Shares of CGEN stock opened at $1.49 on Friday. The firm has a market cap of $132.96 million, a P/E ratio of 74.50 and a beta of 2.64. Compugen has a fifty-two week low of $0.58 and a fifty-two week high of $3.03. The stock’s 50-day moving average is $1.76 and its two-hundred day moving average is $1.87.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.